Trial Profile
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX Made With the Varicella Enhanced Process (VEP)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 26 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 01 Mar 2013 Planned end date changed from 1 May 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned initiation date changed from 1 Jun 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.